Parterships in Clinical Trials Asia Session Spotlight: AstraZeneca’s Strategic Use of Clinical Biomarker in Developing Oncology Clinical Trial Programs

Each week leading up to Partnerships in Clinical Trials Asia, we'll be highlighting a session from the upcoming conference. It will take place October 12-14, 2011, in Shanghai, China. For more information, visit our webpage to download the brochure. 

Featured Session: AstraZeneca’s Strategic Use of Clinical Biomarker in Developing Oncology Clinical Trial Programs
Featured Speaker:  Fred Zheng, Research Clinical Scientist, AstraZeneca
About the Session: Hear how AstraZeneca is reducing study timelines by using a clinical biomarker strategy to support their clinical trial projects, including
how to:

• • Work with providers and CROs to implement a biomarker strategy on an operational level
• • Collaborate with external groups to provide preclinical and clinical data to support the project
• • Use biomarkers for proof of concept and to prospectively select and recruit patients for a particular trial